Capmatinib and tepotinib, highly selective inhibitors of the MET receptor, are both FDA-approved for patients with NSCLC harboring MET exon 14 skipping mutations and have demonstrated intracranial responses in clinical trials [72, 73]. This evidence concerns the gene MET and non-small cell lung carcinoma.